Legal & General Group
TGTX icon

Legal & General Group’s TG Therapeutics TGTX Stock Holding History

Legal & General Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Buy
322,229
+2,526
+0.8% +$103K ﹤0.01% 931
2026
Q1 		$10.6M Sell
319,703
-35,812
-10% -$1.07M ﹤0.01% 1088
2025
Q4 		$10.6M Buy
355,515
+3,905
+1% +$128K ﹤0.01% 1136
2025
Q3 		$12.7M Sell
351,610
-14,531
-4% -$479K ﹤0.01% 1076
2025
Q2 		$13.2M Sell
366,141
-14,991
-4% -$558K ﹤0.01% 1046
2025
Q1 		$15M Sell
381,132
-10,256
-3% -$345K ﹤0.01% 925
2024
Q4 		$11.8M Buy
391,388
+6,552
+2% +$188K ﹤0.01% 1092
2024
Q3 		$9M Buy
384,836
+229,735
+148% +$5.02M ﹤0.01% 1240
2024
Q2 		$2.76M Buy
155,101
+5,845
+4% +$93.3K ﹤0.01% 1795
2024
Q1 		$2.27M Buy
149,256
+2,158
+1% +$34.4K ﹤0.01% 1891
2023
Q4 		$2.51M Buy
147,098
+11,384
+8% +$132K ﹤0.01% 1835
2023
Q3 		$1.13M Buy
135,714
+2,315
+2% +$32.3K ﹤0.01% 2140
2023
Q2 		$3.31M Buy
133,399
+9,262
+7% +$239K ﹤0.01% 1685
2023
Q1 		$1.87M Buy
124,137
+10,085
+9% +$153K ﹤0.01% 1906
2022
Q4 		$1.35M Sell
114,052
-10,304
-8% -$74.8K ﹤0.01% 2048
2022
Q3 		$736K Sell
124,356
-16,625
-12% -$109K ﹤0.01% 2238
2022
Q2 		$599K Buy
140,981
+31,529
+29% +$197K ﹤0.01% 2303
2022
Q1 		$1.04M Buy
109,452
+81
+0.1% +$937 ﹤0.01% 2224
2021
Q4 		$2.08M Buy
109,371
+328
+0.3% +$8.52K ﹤0.01% 2019
2021
Q3 		$3.63M Buy
109,043
+29,739
+38% +$920K ﹤0.01% 1720
2021
Q2 		$3.08M Buy
79,304
+1,711
+2% +$67.2K ﹤0.01% 1774
2021
Q1 		$3.74M Buy
77,593
+2,645
+4% +$127K ﹤0.01% 1715
2020
Q4 		$3.9M Buy
74,948
+13,490
+22% +$456K ﹤0.01% 1589
2020
Q3 		$1.65M Buy
61,458
+37,983
+162% +$874K ﹤0.01% 1849
2020
Q2 		$457K Buy
23,475
+1,800
+8% +$29K ﹤0.01% 2192
2020
Q1 		$213K Sell
21,675
-3,684
-15% -$46.5K ﹤0.01% 2272
2019
Q4 		$281K Buy
25,359
+4,203
+20% +$32K ﹤0.01% 2325
2019
Q3 		$119K Buy
21,156
+3,474
+20% +$24.2K ﹤0.01% 2476
2019
Q2 		$153K Buy
17,682
+7,497
+74% +$56.7K ﹤0.01% 2421
2019
Q1 		$82K Hold
10,185
– – ﹤0.01% 2551
2018
Q4 		$42K Hold
10,185
– – ﹤0.01% 2763
2018
Q3 		$57K Buy
10,185
+894
+10% +$10.2K ﹤0.01% 2711
2018
Q2 		$122K Sell
9,291
-275
-3% -$3.78K ﹤0.01% 2434
2018
Q1 		$136K Sell
9,566
-3,993
-29% -$51K ﹤0.01% 2399
2017
Q4 		$114K Buy
13,559
+1,059
+8% +$9.25K ﹤0.01% 2523
2017
Q3 		$148K Buy
12,500
+1,236
+11% +$14.1K ﹤0.01% 2447
2017
Q2 		$114K Buy
11,264
+1,463
+15% +$16.4K ﹤0.01% 2536
2017
Q1 		$113K Buy
9,801
+384
+4% +$2.76K ﹤0.01% 2475
2016
Q4 		$44K Buy
9,417
+3,139
+50% +$18.4K ﹤0.01% 2915
2016
Q3 		$48K Sell
6,278
-907
-13% -$5.83K ﹤0.01% 2541
2016
Q2 		$43K Hold
7,185
– – ﹤0.01% 2551
2016
Q1 		$65K Buy
7,185
+2,532
+54% +$22.2K ﹤0.01% 2300
2015
Q4 		$55K Hold
4,653
– – ﹤0.01% 2413
2015
Q3 		$46K Hold
4,653
– – ﹤0.01% 2496
2015
Q2 		$75K Hold
4,653
– – ﹤0.01% 2329
2015
Q1 		$75K Hold
4,653
– – ﹤0.01% 2233
2014
Q4 		$76K Hold
4,653
– – ﹤0.01% 2181
2014
Q3 		$50K Buy
+4,653
New +$43.1K ﹤0.01% 2388

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Legal & General Group's TGTX Position: Q2 2026 in Review

Legal & General Group increased its TG Therapeutics (TGTX) stake by 0.79% in Q2 2026, buying an estimated $103K and bringing the position to 322,229 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #931.

Legal & General Group first reported a position in TGTX in Q3 2014 and has held it in 48 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Legal & General Group held 322,229 shares of TG Therapeutics worth $17.7M as of Q2 2026.
  • Legal & General Group bought 2,526 TG Therapeutics shares in Q2 2026, an estimated $103K.
  • TG Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #931 holding.
  • Legal & General Group first reported a position in TG Therapeutics in Q3 2014 and has held it in 48 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.